Arianne Aslamy1,2, Eunjin Oh1, Miwon Ahn1, Abu Saleh Md Moin1, Mariann Chang1, Molly Duncan3, Jeannette Hacker-Stratton4, Mohamed El-Shahawy4, Fouad Kandeel4, Linda A DiMeglio3, Debbie C Thurmond1,2. 1. Department of Molecular and Cellular Endocrinology, Diabetes & Metabolism Research Institute, and Beckman Research Institute of City of Hope, Duarte, California. 2. Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana. 3. Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, and Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Clinical and Translational Research and Cellular Therapeutics, Diabetes & Metabolism Research Institute, and Beckman Research Institute of City of Hope, Duarte, California.
Abstract
Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabetic NOD mice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D human pancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results: DOC2B protein abundance was substantially reduced in prediabetic NOD mouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, human DOC2B levels were reduced over twofold in platelets from new-onset T1D human subjects, and this reduction was mirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.
Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabetic NOD mice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D humanpancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results:DOC2B protein abundance was substantially reduced in prediabetic NOD mouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, humanDOC2B levels were reduced over twofold in platelets from new-onset T1D human subjects, and this reduction was mirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.
Authors: Linda S Wicker; Jan Clark; Heather I Fraser; Valerie E S Garner; Andrea Gonzalez-Munoz; Barry Healy; Sarah Howlett; Kara Hunter; Dan Rainbow; Raymond L Rosa; Luc J Smink; John A Todd; Laurence B Peterson Journal: J Autoimmun Date: 2005-10-28 Impact factor: 7.094
Authors: Anne Q Reuwer; Rienk Nieuwland; Isabelle Fernandez; Vincent Goffin; Claudia M van Tiel; Marianne C L Schaap; René J Berckmans; John J P Kastelein; Marcel Th B Twickler Journal: Thromb Haemost Date: 2009-06 Impact factor: 5.249
Authors: Jia Li; James Cantley; James G Burchfield; Christopher C Meoli; Jacqueline Stöckli; P Tess Whitworth; Himani Pant; Rima Chaudhuri; Alexander J A Groffen; Matthijs Verhage; David E James Journal: Diabetologia Date: 2014-07-09 Impact factor: 10.122
Authors: Giannoula Lakka Klement; Tai-Tung Yip; Flavia Cassiola; Lena Kikuchi; David Cervi; Vladimir Podust; Joseph E Italiano; Erin Wheatley; Abdo Abou-Slaybi; Elise Bender; Nava Almog; Mark W Kieran; Judah Folkman Journal: Blood Date: 2008-11-25 Impact factor: 22.113
Authors: Alex J B Kreutzberger; Volker Kiessling; Catherine A Doyle; Noah Schenk; Clint M Upchurch; Margaret Elmer-Dixon; Amanda E Ward; Julia Preobraschenski; Syed S Hussein; Weronika Tomaka; Patrick Seelheim; Iman Kattan; Megan Harris; Binyong Liang; Anne K Kenworthy; Bimal N Desai; Norbert Leitinger; Arun Anantharam; J David Castle; Lukas K Tamm Journal: Elife Date: 2020-11-09 Impact factor: 8.140